TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients

TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients

The survival of patients with glioblastoma (GBM) is poor. The main cause is the presence of glioma stem cells (GSCs), exceptionally resistant to temozolomide (TMZ) treatment. This last may be related to the heterogeneous expression of ion channels, among them TRPML2. Its mRNA expression was evaluate...

Full description

Bibliographic Details
Main Authors:	Maria Beatrice Morelli, Massimo Nabissi, Consuelo Amantini, Federica Maggi, Lucia Ricci-Vitiani, Roberto Pallini, Giorgio Santoni
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	International Journal of Molecular Sciences
Subjects:	glioblastoma glioma stem cells heterogeneity ion channels transient receptor potential mucolipin-2 temozolomide
Online Access:	https://www.mdpi.com/1422-0067/23/23/15356

Similar Items

Coexpression of TRPML1 and TRPML2 Mucolipin Channels Affects the Survival of Glioblastoma Patients
by: Giorgio Santoni, et al.
Published: (2022-07-01)

Functional In Vitro Assessment of VEGFA/NOTCH2 Signaling Pathway and pRB Proteasomal Degradation and the Clinical Relevance of Mucolipin TRPML2 Overexpression in Glioblastoma Patients
by: Giorgio Santoni, et al.
Published: (2022-01-01)

Transient Receptor Potential Mucolipin-1 Channels in Glioblastoma: Role in Patient’s Survival
by: Maria Beatrice Morelli, et al.
Published: (2019-04-01)

The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment
by: Giorgio Santoni, et al.
Published: (2022-01-01)

ERK Phosphorylation Regulates the Aml1/Runx1 Splice Variants and the TRP Channels Expression during the Differentiation of Glioma Stem Cell Lines
by: Giorgio Santoni, et al.
Published: (2021-08-01)

Temozolomide Chronotherapy in Glioma: A Systematic Review
by: Jason L. Jia, et al.
Published: (2023-02-01)

Down-Regulation of CEND1 Expression Contributes to The Progression and Temozolomide Resistance of Glioma
by: Houjun Zhou, et al.
Published: (2023-04-01)

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
by: Shigeo Ohba, et al.
Published: (2021-05-01)

The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model
by: Przemyslaw Wielgat, et al.
Published: (2021-02-01)

Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas
by: Jiapeng Liu, et al.
Published: (2024-04-01)

Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity
by: Fangting You, et al.
Published: (2023-06-01)

SU4312 Represses Glioma Progression by Inhibiting YAP and Inducing Sensitization to the Effect of Temozolomide
by: Xu Wang, et al.
Published: (2022-08-01)

Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
by: Xiaoying Hou, et al.
Published: (2023-03-01)

Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics
by: Lea Beltzig, et al.
Published: (2022-08-01)

Novel diagnostic and therapeutic approaches to malignant glioma
by: Swiss Medical Weekly
Published: (2011-05-01)

A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients
by: Yurong Li, et al.
Published: (2023-08-01)

Ferritin Is Secreted from Primary Cultured Astrocyte in Response to Iron Treatment via TRPML1-Mediated Exocytosis
by: Xiaoqi Yu, et al.
Published: (2023-10-01)

Long non-coding RNA in glioma: novel genetic players in temozolomide resistance
by: Jungwook Roh, et al.
Published: (2023-12-01)

MiR‐634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf‐ERK signaling pathway
by: Zhigang Tan, et al.
Published: (2018-03-01)

The efficacy of targeted therapy combined with radiotherapy and temozolomide-based chemotherapy in the treatment of glioma: A systemic review and meta-analysis of phase II/III randomized controlled trials
by: Yifan Ma, et al.
Published: (2023-01-01)

Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide
by: Margaux Colin, et al.
Published: (2019-03-01)

Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment
by: Adrian Zając, et al.
Published: (2021-05-01)

Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma
by: Yuanliang Yan, et al.
Published: (2023-09-01)

Hypoxic microenvironment-induced exosomes confer temozolomide resistance in glioma through transfer of pyruvate kinase M2
by: Guofu Li, et al.
Published: (2024-04-01)

Methylation of RARß is a new clinical biomarker for treatment in higher-grade gliomas
by: Cigdem Toprak, et al.
Published: (2023-01-01)

Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin
by: Shao-Wei Feng, et al.
Published: (2022-07-01)

Transcriptomic analysis identifies the neuropeptide cortistatin (CORT) as an inhibitor of temozolomide (TMZ) resistance by suppressing the NF-κB-MGMT signaling axis in human glioma
by: Zongze He, et al.
Published: (2024-05-01)

Cranial Spinal Spreading of Canine Brain Gliomas after Hypofractionated Volumetric-Modulated Arc Radiotherapy and Concomitant Temozolomide Chemotherapy: A Four-Case Report
by: Gaetano Urso, et al.
Published: (2022-09-01)

Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
by: Karoline Almeida Lima, et al.
Published: (2023-04-01)

Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance
by: Ryosuke Maeoka, et al.
Published: (2023-10-01)

A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy
by: Yanzhi Wan, et al.
Published: (2023-11-01)

The role of KDM4A‐mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis
by: Xi‐Xi Li, et al.
Published: (2024-02-01)

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
by: Patrick Roth, et al.
Published: (2020-06-01)

Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges
by: Daisuke Sato, et al.
Published: (2023-06-01)

Survival Analysis and Factors Affecting Treatment Outcome in Glioblastoma Multiforme: A Cohort Study
by: Treesa Thomas, et al.
Published: (2023-09-01)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
by: Yu-Ling Tsai, et al.
Published: (2020-09-01)

A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma
by: Yonghua Cai, et al.
Published: (2022-01-01)

Selected cytostatic drugs in the treatment of brain glioma – literature review
by: Jarosław Bała, et al.
Published: (2021-11-01)

Novel Treatment Strategies for Glioblastoma
by: Stanley S. Stylli
Published: (2020-10-01)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
by: Verena J. Herbener, et al.
Published: (2020-06-01)